JP2017528454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017528454A5 JP2017528454A5 JP2017511933A JP2017511933A JP2017528454A5 JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5 JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017511933 A JP2017511933 A JP 2017511933A JP 2017528454 A5 JP2017528454 A5 JP 2017528454A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- pharmaceutical composition
- composition according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 91
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 90
- 229920001184 polypeptide Polymers 0.000 claims description 89
- 239000008194 pharmaceutical composition Substances 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 208000006673 asthma Diseases 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 11
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 210000002744 extracellular matrix Anatomy 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims description 6
- 208000000884 Airway Obstruction Diseases 0.000 claims description 6
- 208000036065 Airway Remodeling Diseases 0.000 claims description 6
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims description 6
- 230000008602 contraction Effects 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims description 4
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims description 4
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 101710092489 Protein kinase 2 Proteins 0.000 claims description 4
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229940100601 interleukin-6 Drugs 0.000 claims description 4
- 229940071648 metered dose inhaler Drugs 0.000 claims description 4
- 230000002297 mitogenic effect Effects 0.000 claims description 4
- 210000000651 myofibroblast Anatomy 0.000 claims description 4
- 239000006199 nebulizer Substances 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 208000037273 Pathologic Processes Diseases 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 229940124630 bronchodilator Drugs 0.000 claims description 3
- 230000009054 pathological process Effects 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 102000012432 Collagen Type V Human genes 0.000 claims description 2
- 108010022514 Collagen Type V Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102100036202 Serum amyloid P-component Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 210000005091 airway smooth muscle Anatomy 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 108091007231 endothelial receptors Proteins 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960000289 fluticasone propionate Drugs 0.000 claims description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 229940039009 isoproterenol Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical class O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims description 2
- 229960003073 pirfenidone Drugs 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 150000003815 prostacyclins Chemical class 0.000 claims description 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 238000013265 extended release Methods 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- -1 fluticasone furancarboxylic acid ester Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 44
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/473,339 US9890200B2 (en) | 2011-04-12 | 2014-08-29 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US14/473,339 | 2014-08-29 | ||
| PCT/US2015/047390 WO2016033432A1 (en) | 2014-08-29 | 2015-08-28 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017528454A JP2017528454A (ja) | 2017-09-28 |
| JP2017528454A5 true JP2017528454A5 (enExample) | 2018-10-04 |
Family
ID=52583553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511933A Pending JP2017528454A (ja) | 2014-08-29 | 2015-08-28 | 異常な線維芽細胞増殖および細胞外マトリックス沈着を特徴とする疾患、状態、またはプロセスを予防または処置するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9890200B2 (enExample) |
| EP (1) | EP3185883A4 (enExample) |
| JP (1) | JP2017528454A (enExample) |
| KR (1) | KR20170044171A (enExample) |
| CN (1) | CN107073075A (enExample) |
| AU (1) | AU2015308761A1 (enExample) |
| BR (1) | BR112017003731A2 (enExample) |
| CA (1) | CA2958085A1 (enExample) |
| MX (1) | MX2017002476A (enExample) |
| RU (1) | RU2017110093A (enExample) |
| SG (1) | SG11201701135WA (enExample) |
| WO (1) | WO2016033432A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| MX2017008994A (es) * | 2015-01-08 | 2018-09-18 | Moerae Matrix Inc | Formulacion de peptidos inhibidores mk2. |
| BR112017019343A2 (pt) * | 2015-03-12 | 2018-05-02 | Moerae Matrix Inc | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas |
| CN112920256B (zh) * | 2019-11-21 | 2022-08-19 | 上海医药工业研究院 | 一种治疗哮喘的生物肽及其应用 |
| AU2023207395A1 (en) | 2022-01-14 | 2024-07-11 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| ES286422Y (es) | 1982-10-08 | 1986-09-16 | Glaxo Group Limited | Dispositivo para administrar medicamentos a pacientes |
| AT396872B (de) | 1985-07-30 | 1993-12-27 | Glaxo Group Ltd | Gerät zur verabreichung von medikamenten in pulverform |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| WO1993022443A1 (en) | 1992-04-24 | 1993-11-11 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| KR100386337B1 (ko) | 1993-12-09 | 2004-03-24 | 토마스 제퍼슨 대학교 | 진핵세포에서부위-특이적돌연변이를위한화합물과그방법 |
| CA2182792A1 (en) * | 1994-02-17 | 1995-08-24 | Thomas J. Caggiano | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
| DK1808438T3 (da) | 1999-06-29 | 2014-10-27 | Mannkind Corp | Rensning og stabilisering af peptid og proteiner i lægemidler |
| AU2003223718B2 (en) | 2002-04-25 | 2007-08-16 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
| CN101745112A (zh) | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| MX2008012794A (es) * | 2006-04-03 | 2008-10-15 | Teva Pharma | Microparticulas de farmacos. |
| EP2617431B1 (en) | 2007-01-10 | 2017-04-12 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| US8063094B2 (en) | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| DK2349310T3 (da) | 2008-10-20 | 2014-08-11 | Moerae Matrix Inc | Polypeptid til behandling eller forebyggelse af adhæsioner |
| BRPI0922448A2 (pt) | 2008-12-10 | 2021-02-17 | Purdue Research Foundation | inibidor com base em peptídeo penetrante celular de quinases |
| AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US20110288036A1 (en) | 2010-05-24 | 2011-11-24 | Cynthia Lander | Methods for Treating or Preventing Vascular Graft Failure |
| ES2711670T3 (es) | 2011-04-12 | 2019-05-06 | Moerae Matrix Inc | Composiciones y métodos para la prevención o tratamiento de la fibrosis pulmonar |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2014
- 2014-08-29 US US14/473,339 patent/US9890200B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 WO PCT/US2015/047390 patent/WO2016033432A1/en not_active Ceased
- 2015-08-28 AU AU2015308761A patent/AU2015308761A1/en not_active Abandoned
- 2015-08-28 EP EP15835631.1A patent/EP3185883A4/en not_active Withdrawn
- 2015-08-28 JP JP2017511933A patent/JP2017528454A/ja active Pending
- 2015-08-28 RU RU2017110093A patent/RU2017110093A/ru not_active Application Discontinuation
- 2015-08-28 SG SG11201701135WA patent/SG11201701135WA/en unknown
- 2015-08-28 KR KR1020177007622A patent/KR20170044171A/ko not_active Withdrawn
- 2015-08-28 CA CA2958085A patent/CA2958085A1/en not_active Abandoned
- 2015-08-28 BR BR112017003731A patent/BR112017003731A2/pt not_active IP Right Cessation
- 2015-08-28 CN CN201580058532.3A patent/CN107073075A/zh active Pending
- 2015-08-28 MX MX2017002476A patent/MX2017002476A/es unknown
-
2017
- 2017-12-27 US US15/855,398 patent/US10562947B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533235A5 (enExample) | ||
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| JP2017528454A5 (enExample) | ||
| JP2010533181A5 (enExample) | ||
| JP6889201B2 (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| US20130216608A1 (en) | Airway Administration of Angiogenesis Inhibitors | |
| JP2008540563A (ja) | 肺疾患を処置するためのモノクローナル抗体の霧状化 | |
| JP2002539072A5 (enExample) | ||
| JP2015505303A5 (enExample) | ||
| JP2016516016A5 (enExample) | ||
| RU2017110093A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| JP2010539243A (ja) | 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤 | |
| JP2002541213A5 (enExample) | ||
| Li et al. | Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization | |
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases | |
| CN103429610A (zh) | 用于抑制炎症的肽 | |
| CN106075401A (zh) | 白介素35在制备治疗自身免疫性皮肤病药物中的用途和治疗药物以及IL‑35‑Fc融合蛋白 | |
| US20150313967A1 (en) | Methods and Agents for Wound Healing | |
| RU2016140332A (ru) | Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) | |
| CN102584976A (zh) | 一种人血清淀粉样蛋白a1及其制备方法和应用 | |
| RS55154B1 (sr) | Interferon beta za upotrebu u lečenju bolesti donjeg respiratornog trakta uzrokovane gripom | |
| Laurina et al. | Growth factors/cytokines/defensins and apoptosis in periodontal pathologies | |
| Wang et al. | The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis | |
| Laurent et al. | TGF-beta antibodies: a novel treatment for pulmonary fibrosis? | |
| Prabu et al. | Insulin-Based Drug Delivery Systems |